Health Canada
- Status: approved
Proactive TDM-based dosing of guselkumab (Proactive TDM-based dosing of guselkumab) regulatory status in Canada.
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. Health Canada has authorised it.
University Hospital, Ghent is the originator. The local marketing authorisation holder may differ — check the official source linked above.